Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 1926

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 7
Chunk 1926
---
 Cancer’s common stock to be $5.50
in fiscal years 2024 based on a third-party valuation.

The Company determined
that the fair value per share of NeuroNos’ common stock to be $0.14
at the grant date in fiscal year 2025 based on a third-party valuation.

The following summarizes the components of stock-based
compensation expense which included stock options and restricted stock for the years ended March 31, 2025 and March 31, 2024, in thousands:

 SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE

    Year Ended 

    March 31, 

    2025  
    2024 

    Research and development 
    $471  
    $4,480 
  
    General and administrative 
     8,675  
     16,857 

    Total stock-based compensation expense 
    $9,146 
    $21,337 

Warrants

A summary of the Company’s outstanding warrants
as of March 31, 2025 is as follows:

 SUMMARY
OF COMPANY’S OUTSTANDING WARRANTS

    Warrant Holders 
    Number of Warrants  
    Exercise Price  
    Intrinsic Value (in thousands)  
    Date of Expiration

    NitricGen agreement 
     80,000  
    $6.90  
     -  
    January 2028
  
    Avenue agreement 
     233,843  
    $0.38  
     -  
    June 2028
  
    March 2024 raise 
     9,638,556  
    $2.25  
     -  
    March 2027
  
    Avenue extension agreement 
     100,000  
    $1.28  
     -  
    June 2029
  
    September 2024 equity offering 
     39,887,081  
    $0.38  
     -  
    September 2029
  
    September 2024 debt instrument 
     15,159,504  
    $0.38  
     -  
    September 2029
  
    Sub-total 
     65,098,984  
    $0.67  
    $-  

    Pre-funded warrants 
     12,127,247  
    $0.0001